Boozman Urges Continued Federal Investment in Scientific and Biomedical Research, Strengthened Capacity in Heartland

U.S. Senator John Boozman (R-AR) questioned officials with the National Institutes of Health (NIH) on the impact of investments in biomedical, cancer and drug abuse research at a hearing examining the president's Fiscal Year 2027 budget request.

Boozman touted the critical role the IDeA program has played in states like Arkansas that have historically received a smaller share of federal biomedical research funding yet face some of the nation's highest rates of chronic disease and adverse health outcomes.

The senator also cited the rising incidence of cancer among younger adults who would otherwise be considered healthy and at low risk, and pushed for an update on research initiatives underway to identify potential causes and prevention strategies.

Boozman, a member of the Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, concluded by referencing the emergence of a powerful new synthetic opioid, reported to be even stronger than fentanyl, recently linked to a death in Arkansas and sought assurance that federal research and resources continue to adapt quickly enough to help states tackle these rapidly evolving, lethal drug threats.